The report of Global Gestational Trophoblastic Disease Market by Type (Hydatidiform mole, Choriocarcinoma, Placental-site trophoblastic tumor, Epithelioid trophoblastic tumor, others), Treatment (Surgery, Chemotherapy, Suction dilation and curettage (D&C), Radiation Therapy), End user (Hospital and clinics, Diagnostic centers, others) and Region (North America, Europe, Middle East & Africa, South America, Asia Pacific) is expected to reach US$ XX Mn. by 2027, at a CAGR of 4.10 % during a forecast period.
The report contains a detailed study of factors that will drive and restrain the growth of the gestational trophoblastic disease market globally. Increase in ectopic pregnancies is a major factor which causes gestational trophoblastic disease. According to the NCBI (National Center for Biotechnology Information), the risk of ectopic pregnancy is 20 times higher in women who smoke. However, high risks of complications and recurrence that may occur after the therapy and treatment procedure may hamper the growth of the market during 2019-2027.
Hydatidiform mole segment held the largest market share in 2019 and is projected to grow at the highest CAGR of XX.17% to reach US$ XX Mn by 2027.
Hydatidiform mole segment is expected to continue to hold the largest XX.17% share in gestational trophoblastic disease market owing to it is the most common form of the gestational trophoblastic disease. Chemotherapy segment holds the second-largest share in the gestational trophoblastic disease market and it is expected to grow at a CAGR of XX.01 % during 2019-2027.
North America region is expected to account for the largest XX.53% gestational trophoblastic disease market share by 2027.
The market in North America is expected to dominate the GTD market during the forecast period because of the favorable reimbursement scenario and the increased awareness about the disease in this region. The European GTD market is expected to be the second-largest owing to the substantial support of the government in R&D in this field.
Key players operating in the Global Gestational Trophoblastic Disease Market are Hikma Pharmaceuticals PLC, Pfizer Inc., Bristol-Myers Squibb Company, Antares Pharma, Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., BP Pharmaceuticals Laboratories Company, Fresenius Kabi AG, Accord Healthcare, Inc., Eli Lilly and Company, Sanofi, Bayer AG, Amgen Inc, and Merck
Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the Global Gestational Trophoblastic Disease Market. The report encompasses the market by different segments and region, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics, and future opportunities that might exist in the Global Gestational Trophoblastic Disease Market. The driving forces, as well as considerable restraints, have been explained in depth. in addition to this, competitive landscape describing the strategic growth of the competitors have been taken into consideration for enhancing market know-how of our clients and at the same time explain Global Gestational Trophoblastic Disease Market positioning of competitors.
Browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on “Global Gestational Trophoblastic Disease Market”
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051, Maharashtra, India.
+91 9607195908